The DOI matches its Crossref record.
334-OR: pemvidutide (ALT-801), a balanced (1: 1) GLP-1/glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight/obesity
Abstract
Background: Weight loss is the cornerstone of therapy for people with overweight/obesity. Pemvidutide is a dual GLP-1/glucagon receptor agonist that provides GLP-1/glucagon agonism in a balanced (1:1) ratio, which is hypothesized to enhance weight loss and minimize gastrointestinal intolerance. Methods: 34 subjects with overweight/obesity (BMI 25.0-40.0 kg/m2) without diabetes were randomized in double-blind manner to pemvidutide (1.2, 1.8 or 2.4 mg) or placebo subcutaneously weekly for 12 weeks without dose titration or lifestyle therapy. Study endpoints included safety/tolerability, weight loss and cardiometabolic outcomes. Results: At 12 weeks, significant weight loss was achieved with 1.8 mg (10.3%) and 2.4 mg (9.0%) of pemvidutide, and significant improvements or trends in cardiometabolic risk factors were observed at all pemvidutide doses (Table 1) . No increases in heart rate, fasting glucose or HbA1c were observed in any group. Mild, transient nausea was the most frequent adverse event (AE) ; no severe/serious AEs or AE-related study discontinuations were reported. Conclusion: Pemvidutide induces robust weight loss and improves cardiometabolic risk factors without dose titration. These data support the development of pemvidutide as a promising treatment for obesity and its comorbidities. Disclosure: S.Klein: Advisory Panel; Altimmune, Consultant; Janssen Research & Development, LLC, ProSciento, Research Support; Janssen Research & Development, LLC. S.K.Browne: Employee; Altimmune. J.J.Nestor: Consultant; Altimmune, Employee; EuMederis Pharmaceutials, Inc., Mederis Diabetes, LLC, Spitfire Pharma, Inc. M.Harris: Employee; Altimmune. A.Suyundikov: Employee; Altimmune. R.Casper: Employee; Altimmune. S.M.Steele: Employee; Altimmune. J.D.Payne: None. V.Krishnan: Employee; Altimmune. M.Roberts: Employee; Altimmune. Funding: Altimmune, Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemvidutide (ALT-801) is another unimolecular once weekly GLP-1/glucagon agonist undergoing a phase 2 trial as obesity treatment, following a phase 1 trial demonstrating up to 10.3% WL at 12 weeks [73].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [73]
In the citing paper
“No discontinuations were observed.”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [91]
In the citing paper
“The most frequent AE noted were gastrointestinal.”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [91]
In the citing paper
“The MAD cohort randomized to 420 mg monthly lost 14.5% of their total body weight after receiving 3 doses of treatment and maintained 10% total weight loss approximately 2.5 months after last dose.”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [91]
Citations
Cites
Still being checked.
Cited by
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Pemvidutide (ALT-801) is another unimolecular once weekly GLP-1/glucagon agonist undergoing a phase 2 trial as obesity treatment, following a phase 1 trial demonstrating up to 10.3% WL at 12 weeks [73].”
InfluentialAlfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
Nicze, M., Dec, A., Borówka, M., Krzyżak, D., Bołdys, A., Bułdak, Ł., & Okopień, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158202 · Cited by 33
Effect of GLP-1 receptor agonists on body composition
Bhandarkar, A. P., Bhat, S., & Kapoor, N. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000934 · Cited by 29
Metadata
- Authors
- KLEIN, S., NESTOR, J. J., HARRIS, M. S., SUYUNDIKOV, A., CASPER, R., STEELE, S. M., PAYNE, J. D., KRISHNAN, V., ROBERTS, M. S., & BROWNE, S. K.
- Affiliations
- St. Louis, MO, South San Francisco, CA, Gaithersburg, MD
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2022-06-01
- Volume
- 71
- Issue
- Supplement_1
- ISSN
- 0012-1797 (ISSN-L)
- OpenAlex
- W4281699715
- Cited by
- 21
- References
- 0
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 1
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, overweight, weight loss, cardiometabolic risk factors, nausea, dose titration, drug safety and tolerability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 334-OR: pemvidutide (ALT-801), a balanced (1: 1) GLP-1/glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight/obesity. https://app.cochat.ai/papers/10.2337/db22-334-or
- The paper
- KLEIN, S., NESTOR, J. J., HARRIS, M. S., SUYUNDIKOV, A., CASPER, R., STEELE, S. M., PAYNE, J. D., KRISHNAN, V., ROBERTS, M. S., & BROWNE, S. K. (2022). 334-OR: pemvidutide (ALT-801), a balanced (1: 1) GLP-1/glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight/obesity. Diabetes. https://doi.org/10.2337/db22-334-or
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.